Erratum: Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study (PLoS Medicine (2017) 14:4 (e1002277) DOI: 10.1371/journal.pmed.1002277);Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study

PLoS Medicine

Volumn 14, Issue 4, 2017, Pages

  ten Haaf, Kevin ^a   Jeon, Jihyoun ^b   Tammemägi, Martin C ^c   Han, Summer S ^d   Kong, Chung Yin ^e   Plevritis, Sylvia K ^d   Feuer, Eric J ^f   de Koning, Harry J ^a   Steyerberg, Ewout W ^a   Meza, Rafael ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MICHIGAN   (United States)

^c BROCK UNIVERSITY   (Canada)

^d STANFORD UNIVERSITY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; CALIBRATION; CANCER RISK; CANCER SCREENING; CLINICAL FEATURE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DECISION CURVE ANALYSIS; FEMALE; FREQUENCY DISCRIMINATION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL PARAMETERS; MODEL; MORTALITY RISK; OVARY CANCER; PREDICTION; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY; VALIDATION STUDY; EARLY CANCER DIAGNOSIS; LUNG NEOPLASMS; MASS SCREENING; MIDDLE AGED; PATIENT SELECTION; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; THEORETICAL MODEL;

AGED; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, THEORETICAL; PATIENT SELECTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 85018341388     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1003403     Document Type: Erratum

References (78)

1. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409. doi: 10.1056/NEJMoa1102873 21714641
2. de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160(5):311–20. doi: 10.7326/M13-2316 24379002
3. Moyer VA, Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330–8. doi: 10.7326/M13-2771 24378917
4. Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. Ann Intern Med. 2013;159(6):411–20. doi: 10.7326/0003-4819-159-6-201309170-00690 23897166
5. Roberts H, Walker-Dilks C, Sivjee K, Ung Y, Yasufuku K, Hey A, et al. Screening high-risk populations for lung cancer: guideline recommendations. J Thorac Oncol. 2013;8(10):1232–7. doi: 10.1097/JTO.0b013e31829fd3d5 24457233
6. Tammemägi M, Hader J, Yu M, Govind K, Svara E, Yurcan M, et al. P1.03–059: organized high risk lung cancer screening in Ontario, Canada: a multi-centre prospective evaluation. J Thorac Oncol. 2017;12(1):S579.
7. Field JK, Hansell DM, Duffy SW, Baldwin DR, CT screening for lung cancer: countdown to implementation. Lancet Oncol. 2013;14(13):e591–600. doi: 10.1016/S1470-2045(13)70293-6 24275132
8. Horeweg N, van Rosmalen J, Heuvelmans MA, van der Aalst CM, Vliegenthart R, Scholten ET, et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol. 2014;15(12):1332–41. doi: 10.1016/S1470-2045(14)70389-4 25282285
9. van der Aalst CM, ten Haaf K, de Koning HJ, Lung cancer screening: latest developments and unanswered questions. Lancet Respir Med. 2016;4(9):749–61. doi: 10.1016/S2213-2600(16)30200-4 27599248
10. Tammemägi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368(8):728–36. doi: 10.1056/NEJMoa1211776 23425165
11. Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med. 2013;369(3):245–54. doi: 10.1056/NEJMoa1301851 23863051
12. Katki HA, Kovalchik SA, Berg CD, Cheung LC, Chaturvedi AK, Development and validation of risk models to select ever-smokers for CT lung cancer screening. JAMA. 2016;315(21):2300–11. doi: 10.1001/jama.2016.6255 27179989
13. Tammemagi MC, Church TR, Hocking WG, Silvestri GA, Kvale PA, Riley TL, et al. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med. 2014;11(12):e1001764. doi: 10.1371/journal.pmed.1001764 25460915
14. Jaklitsch MT, Jacobson FL, Austin JHM, Field JK, Jett JR, Keshavjee S, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012;144(1):33–8. doi: 10.1016/j.jtcvs.2012.05.060 22710039
15. Collins GS, Moons KGM, Comparing risk prediction models. BMJ. 2012;344:e3186. doi: 10.1136/bmj.e3186 22628131
16. Altman DG, Vergouwe Y, Royston P, Moons KGM, Prognosis and prognostic research: validating a prognostic model. BMJ. 2009;338:b605. doi: 10.1136/bmj.b605 19477892
17. Siontis GCM, Tzoulaki I, Siontis KC, Ioannidis JPA, Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ. 2012;344:e3318. doi: 10.1136/bmj.e3318 22628003
18. Vergouwe Y, Steyerberg EW, Eijkemans MJC, Habbema JDF, Substantial effective sample sizes were required for external validation studies of predictive logistic regression models. J Clin Epidemiol. 2005;58(5):475–83. doi: 10.1016/j.jclinepi.2004.06.017 15845334
19. Collins GS, Ogundimu EO, Altman DG, Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. Stat Med. 2016;35(2):214–26. doi: 10.1002/sim.6787 26553135
20. D’Amelio AM, JrCassidy A, Asomaning K, Raji OY, Duffy SW, Field JK, et al. Comparison of discriminatory power and accuracy of three lung cancer risk models. Br J Cancer. 2010;103(3):423–9. doi: 10.1038/sj.bjc.6605759 20588271
21. Li K, Hüsing A, Sookthai D, Bergmann M, Boeing H, Becker N, et al. Selecting high-risk individuals for lung cancer screening: a prospective evaluation of existing risk models and eligibility criteria in the German EPIC cohort. Cancer Prev Res (Phila). 2015;8(9):777–85.
22. National Lung Screening Trial Research TeamAberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, et al. The National Lung Screening Trial: overview and study design. Radiology. 2011;258(1):243–53. doi: 10.1148/radiol.10091808 21045183
23. Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011;306(17):1865–73. doi: 10.1001/jama.2011.1591 22031728
24. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(6, Suppl 1):273S–309S.
25. ten Haaf K, de Koning HJ, Should never-smokers at increased risk for lung cancer be screened?J Thorac Oncol. 2015;10(9):1285–91. doi: 10.1097/JTO.0000000000000593 26287320
26. Etzel CJ, Kachroo S, Liu M, D’Amelio A, Dong Q, Cote ML, et al. Development and validation of a lung cancer risk prediction model for African-Americans. Cancer Prev Res (Phila). 2008;1(4):255–65.
27. Li H, Yang L, Zhao X, Wang J, Qian J, Chen H, et al. Prediction of lung cancer risk in a Chinese population using a multifactorial genetic model. BMC Med Genet. 2012;13(1):118.
28. Park S, Nam B-H, Yang H-R, Lee JA, Lim H, Han JT, et al. Individualized risk prediction model for lung cancer in Korean men. PLoS ONE. 2013;8(2):e54823. doi: 10.1371/journal.pone.0054823 23408946
29. El-Zein RA, Lopez MS, D’Amelio AM, JrLiu M, Munden RF, Christiani D, et al. The cytokinesis blocked micronucleus assay as a strong predictor of lung cancer: extension of a lung cancer risk prediction model. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2462–70. doi: 10.1158/1055-9965.EPI-14-0462 25172871
30. Maisonneuve P, Bagnardi V, Bellomi M, Spaggiari L, Pelosi G, Rampinelli C, et al. Lung cancer risk prediction to select smokers for screening CT—a model based on the Italian COSMOS trial. Cancer Prev Res (Phila). 2011;4(11):1778–89.
31. Spitz MR, Etzel CJ, Dong Q, Amos CI, Wei Q, Wu X, et al. an expanded risk prediction model for lung cancer. Cancer Prev Res (Phila). 2008;1(4):250–4.
32. Hoggart C, Brennan P, Tjonneland A, Vogel U, Overvad K, Østergaard JN, et al. A risk model for lung cancer incidence. Cancer Prev Res (Phila). 2012;5(6):834–46.
33. McWilliams A, Tammemagi MC, Mayo JR, Roberts H, Liu G, Soghrati K, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med. 2013;369(10):910–9. doi: 10.1056/NEJMoa1214726 24004118
34. Hippisley-Cox J, Coupland C, Identifying patients with suspected lung cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract. 2011;61(592):e715–23. doi: 10.3399/bjgp11X606627 22054335
35. Iyen-Omofoman B, Tata LJ, Baldwin DR, Smith CJP, Hubbard RB, Using socio-demographic and early clinical features in general practice to identify people with lung cancer earlier. Thorax. 2013;68(5):451–9. doi: 10.1136/thoraxjnl-2012-202348 23321602
36. Young RP, Hopkins RJ, Hay BA, Epton MJ, Mills GD, Black PN, et al. A gene-based risk score for lung cancer susceptibility in smokers and ex-smokers. Postgrad Med J. 2009;85(1008):515–24. doi: 10.1136/pgmj.2008.077107 19789190
37. Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst. 2007;99(9):715–26. doi: 10.1093/jnci/djk153 17470739
38. Raji OY, Duffy SW, Agbaje OF, Baker SG, Christiani DC, Cassidy A, et al. Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a case–control and cohort validation study. Ann Intern Med. 2012;157(4):242–50. doi: 10.7326/0003-4819-157-4-201208210-00004 22910935
39. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst. 2003;95(6):470–8. 12644540
40. Knoke JD, Burns DM, Thun MJ, The change in excess risk of lung cancer attributable to smoking following smoking cessation: an examination of different analytic approaches using CPS-I data. Cancer Causes Control. 2007;19(2):207–19. doi: 10.1007/s10552-007-9086-5 17992575
41. Hazelton WD, Clements MS, Moolgavkar SH, Multistage carcinogenesis and lung cancer mortality in three cohorts. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1171–81. doi: 10.1158/1055-9965.EPI-04-0756 15894668
42. Hazelton WD, Jeon J, Meza R, Moolgavkar SH, Chapter 8: the FHCRC lung cancer model. Risk Anal. 2012;32:S99–116. doi: 10.1111/j.1539-6924.2011.01681.x 22882896
43. Meza R, Hazelton W, Colditz G, Moolgavkar S, Analysis of lung cancer incidence in the Nurses’ Health and the Health Professionals’ Follow-Up Studies using a multistage carcinogenesis model. Cancer Causes Control. 2008;19(3):317–28. doi: 10.1007/s10552-007-9094-5 18058248
44. Cassidy A, Myles JP, van Tongeren M, Page RD, Liloglou T, Duffy SW, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer. 2008;98(2):270–6. doi: 10.1038/sj.bjc.6604158 18087271
45. Gorelick MH, Bias arising from missing data in predictive models. J Clin Epidemiol. 2006;59(10):1115–23. doi: 10.1016/j.jclinepi.2004.11.029 16980153
46. National Lung Screening Trial Research TeamAberle DR, Adams AM, Berg CD, Clapp JD, Clingan KL, et al. Baseline characteristics of participants in the randomized National Lung Screening Trial. J Natl Cancer Inst. 2010;102(23):1771–9. doi: 10.1093/jnci/djq434 21119104
47. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al., editors. SEER Cancer Statistics Review, 1975–2012. Bethesda (Maryland): National Cancer Institute; 2015Apr [cited 2017 Mar 1]. http://seer.cancer.gov/csr/1975_2012/.
48. National Cancer InstituteCancer stat facts: lung and bronchus cancer. Bethesda (Maryland): National Cancer Institute; 2016 [cited 2016 Mar 4]. http://seer.cancer.gov/statfacts/html/lungb.html.
49. Jolani S, Debray T, Koffijberg H, Buuren S, Moons KGM, Imputation of systematically missing predictors in an individual participant data meta-analysis: a generalized approach using MICE. Stat Med. 2015;34(11):1841–63. doi: 10.1002/sim.6451 25663182
50. Steyerberg EW, Vergouwe Y, Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35(29):1925–31. doi: 10.1093/eurheartj/ehu207 24898551
51. Etzioni R, Gulati R, Mallinger L, Mandelblatt J, Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med. 2013;158(11):831–8. doi: 10.7326/0003-4819-158-11-201306040-00008 23732716
52. Patz EF, JrPinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammenägi MC, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014;174(2):269–74. doi: 10.1001/jamainternmed.2013.12738 24322569
53. ten Haaf K, de Koning HJ, Overdiagnosis in lung cancer screening: why modelling is essential. J Epidemiol Community Health. 2015;69(11):1035–9. doi: 10.1136/jech-2014-204079 26071497
54. Vickers AJ, Cronin AM, Everything you always wanted to know about evaluating prediction models (but were too afraid to ask). Urology. 2010;76(6):1298–301. doi: 10.1016/j.urology.2010.06.019 21030068
55. R Core TeamR: a language and environment for statistical computing. Version 3.3.0. Vienna: R Foundation for Statistical Computing; 2016.
56. Royston P, Moons KGM, Altman DG, Vergouwe Y, Prognosis and prognostic research: developing a prognostic model. BMJ. 2009;338:b604. doi: 10.1136/bmj.b604 19336487
57. Van Calster B, Nieboer D, Vergouwe Y, De Cock B, Pencina MJ, Steyerberg EW, A calibration hierarchy for risk models was defined: from utopia to empirical data. J Clin Epidemiol. 2016;74:167–76. doi: 10.1016/j.jclinepi.2015.12.005 26772608
58. Harrell FE Jr. rms: regression modeling strategies. Version 4.3–1. Comprehensive R Archive Network; 2014 [cited 2017 Mar 1]. http://CRAN.R-project.org/package=rms.
59. Steyerberg EW, Clinical prediction models: a practical approach to development, validation, and updating. New York: Springer; 2009.
60. Vickers AJ, Elkin EB, Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565–74. doi: 10.1177/0272989X06295361 17099194
61. Vickers AJ, Cronin AM, Elkin EB, Gonen M, Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8:53. doi: 10.1186/1472-6947-8-53 19036144
62. van Buuren S, Groothuis-Oudshoorn K, mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):67.
63. Rubin DB, Multiple imputation for nonresponse in surveys. New York: Wiley; 1987.
64. Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1–73. doi: 10.7326/M14-0698 25560730
65. van der Heijden GJMG, Donders ART, Stijnen T, Moons KGM, Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example. J Clin Epidemiol. 2006;59(10):1102–9. doi: 10.1016/j.jclinepi.2006.01.015 16980151
66. Steyerberg EW, Eijkemans MJC, Boersma E, Habbema JDF, Equally valid models gave divergent predictions for mortality in acute myocardial infarction patients in a comparison of logical regression models. J Clin Epidemiol. 2005;58(4):383–90. doi: 10.1016/j.jclinepi.2004.07.008 15862724
67. Vergouwe Y, Moons KGM, Steyerberg EW, External validity of risk models: use of benchmark values to disentangle a case-mix effect from incorrect coefficients. Am J Epidemiol. 2010;172(8):971–80. doi: 10.1093/aje/kwq223 20807737
68. Debray TPA, Vergouwe Y, Koffijberg H, Nieboer D, Steyerberg EW, Moons KGM, A new framework to enhance the interpretation of external validation studies of clinical prediction models. J Clin Epidemiol. 2015;68(3):279–89. doi: 10.1016/j.jclinepi.2014.06.018 25179855
69. Patz EF, JrGreco E, Gatsonis C, Pinsky P, Kramer BS, Aberle DR, Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial. Lancet Oncol. 2016;17(5):590–9. doi: 10.1016/S1470-2045(15)00621-X 27009070
70. Royston P, Altman DG, Sauerbrei W, Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006;25(1):127–41. doi: 10.1002/sim.2331 16217841
71. Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368(4):351–64. doi: 10.1056/NEJMsa1211127 23343064
72. McRonald FE, Yadegarfar G, Baldwin DR, Devaraj A, Brain KE, Eisen T, et al. The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. Cancer Prev Res (Phila). 2014;7(3):362.
73. Brock UniversityLung cancer risk calculators. St. Catharines (Ontario): Brock University; 2016 [cited 2016 Dec 19]. https://brocku.ca/lung-cancer-risk-calculator.
74. Memorial Sloan Kettering Cancer CenterLung cancer screening decision tool. New York:Memorial Sloan Kettering Cancer Center; 2016 [cited 2016 Dec 19]. https://www.mskcc.org/cancer-care/types/lung/screening/lung-screening-decision-tool.
75. Lau YK, Caverly TJ, Cao P, Cherng ST, West M, Gaber C, et al. Evaluation of a personalized, web-based decision aid for lung cancer screening. Am J Prev Med. 2015;49(6):e125–9. doi: 10.1016/j.amepre.2015.07.027 26456873
76. University of MichiganLung cancer CT screening [decision aid]. Ann Arbor: University of Michigan; 2016 [cited 2016 Dec 21]. http://www.shouldiscreen.com/.
77. American College of RadiologyLung cancer screening resources. Reston (Virginia): American College of Radiology; 2016 [cited 2016 Dec 21]. https://www.acr.org/Quality-Safety/Resources/Lung-Imaging-Resources.
78. Jensen TS, Chin J, Ashby L, Hermansen J, Hutter JD, Decision memo for screening for lung cancer with low dose computed tomography (LDCT) (CAG-00439N). Baltimore: Centers for Medicare & Medicaid Services; 2015 [cited 2016 Aug 15]. https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274.